Journal Mobile Options
Table of Contents
Vol. 13, No. 3, 2007
Issue release date: June 2007
Eur Addict Res 2007;13:144–147
(DOI:10.1159/000101550)

Pathways into Receiving a Prescription for Diamorphine (Heroin) for the Treatment of Opiate Dependence in the United Kingdom

Metrebian N. · Mott J. · Carnwath Z. · Carnwath T. · Stimson G.V. · Sell L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

In the UK, few doctors prescribe diamorphine for the treatment of opiate dependence to a small number of patients. A retrospective case note review of patients receiving diamorphine in 2000 was conducted in the UK to determine how and why these patients came to receive a prescription for diamorphine. Patient eligibility criteria were examined together with doctors’ stated reasons for initiating a diamorphine (heroin) prescription. Two hundred and ten sets of patients’ case notes were reviewed at 27 of the 42 (64%) drug clinics in England and Wales where diamorphine was prescribed by the doctor. There appeared to be a general consensus among the few doctors who had prescribed diamorphine that it was a treatment of last resort, for those with long histories of heroin use and injecting, and those who had not responded sufficiently well to previous other treatments. However, there was also a small number of patients initiated on diamorphine without ever having previously received opiate treatments and some because they were experiencing problems injecting methadone. This reflects the UK history of the individual doctor’s clinical autonomy in deciding when diamorphine is appropriate and the previous lack of nationally agreed patient eligibility criteria.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Department of Health, Scottish Office Home and Health Department Welsh Office Drug Misuse and Dependence: Guidelines on Clinical Management. London, The Stationary Office, 1991.
  2. Department of Health and Social Security: Guidelines of Good Practice in the Treatment of Drug Misuse. London, The Stationary Office, 1984.
  3. Department of Health Drug Misuse and Dependence: Guidelines on Clinical Management. London, The Stationary Office, 1999.
  4. Metrebian N, Carnwath T, Stimson GV, Storz T: Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction 2002;97:1155–1161.
  5. Stimson GV, Metrebian N: Prescribing Heroin: What Is the Evidence? London, Joseph Rowntree Foundation Drug and Alcohol Research Programme, 2004.
  6. National Treatment Agency for Substance Misuse: Injectable Heroin (and Injectable Methadone): Potential Roles in Drug Treatment. London, National Treatment Agency, 2003.
  7. Home Office: Updated Drug Strategy. London, HMSO, 2002.
  8. Sell L, Zador D: Patients prescribed injectable heroin or methadone – their opinions and experiences of treatment. Addiction 2004;99:442–449.
  9. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A: Feasibility, safety and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001;358:1417–1420.
  10. Van den Brink W, Hendricks VM, Blanken P, Koeter MWJ, van Zwieten BJ, van Ree JM: Medical prescription of heroin to treatment resistant heroin addicts: two randomized controlled trials. BMJ 2003;327:310–316.
  11. Blanken P, Hendriks VM, Koeter MW, van Ree JM, van den Brink W: Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Addiction 2005;100:89–95.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00